Key points from article :
Eos Advisory in strategic partnership with Kineticos to co-invest in early-stage Scottish life sciences companies.
Aim to invest more than £10m over five years in oncology-focused firms.
Medical needs in oncology, neurosciences and rare diseases, approaches to gene & cell therapies, and precision medicine.
Kineticos has a biotech advisory practice and a fund to invest in the advancement and commercialisation of clinical research.
Eos will engage with Scottish Enterprise and other private and public investors to support its co-investments.
"...help find and fund breakthrough ideas from Scotland's brightest life science entrepreneurs," - Kevin Grainger, founder of Eos.
"...will have a significant impact on improving the early diagnosis and treatment of cancer globally."
